Rodman & Renshaw Maintains SuperGen Market Outperform, $5 PT

Rodman & Renshaw maintained its SuperGen (SUPG) Market Outperform rating and $5 price target in a research report published today. In the report, Rodman & Renshaw states, "We believe that the combined companies' pipeline could be valued at par with the average of a comparable group of oncology drug developers, which trade at an enterprise value of slightly greater than $300MM." Shares of SuperGen were trading at $2.85 at the time of posting, down 5.94% from Tuesday's market close.